We are live on
!
Find out more
SA
Sovran Advisors Portfolio holdings
AUM
$1.34B
1-Year Est. Return
21.63%
This Fund
S&P 500
This Quarter
Est. Return
-2.44%
1 Year Est. Return
+21.63%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$770M
AUM Growth
+$68.8M
(+9.8%)
Cap. Flow
+$130M
Cap. Flow
% of AUM
16.87%
Top 10 Holdings %
Top 10 Hldgs %
19.85%
Holding
481
New
73
Increased
256
Reduced
119
Closed
26
Avg Time Held
0.8
quarters
Top 10 Avg Time Held
0.8
quarters
Top 20 Avg Time Held
0.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$7.21M |
| 2 |
Apple
AAPL
|
+$6.33M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$5.14M |
| 4 |
Microsoft
MSFT
|
+$5M |
| 5 |
Meta Platforms (Facebook)
META
|
+$4.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PIMCO Dynamic Income Fund
PDI
|
+$2.67M |
| 2 |
Johnson & Johnson
JNJ
|
+$2.63M |
| 3 |
Celldex Therapeutics
CLDX
|
+$2.6M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$2.6M |
| 5 |
iShares MSCI EAFE Growth ETF
EFG
|
+$2.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 72.84% |
| 2 | Technology | 9.26% |
| 3 | Healthcare | 4.68% |
| 4 | Consumer Discretionary | 3.53% |
| 5 | Financials | 2.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Summit Therapeutics
SMMT
$12.4B
| $3.61M | 0.47% |
146,528
+29,354
| +25% | +$589K |
2024 Q4
1 quarter
|
|
52
iShares MSCI Emerging Markets ex China ETF
EMXC
$25.4B
| $3.49M | 0.45% |
64,270
-3,948
| -6% | -$221K |
2024 Q4
1 quarter
|
|
53
Invesco S&P 500 High Dividend Low Volatility ETF
SPHD
$3.21B
| $3.43M | 0.45% |
72,767
+6,617
| +10% | +$326K |
2024 Q4
1 quarter
|
|
54
iShares Morningstar Mid-Cap Growth ETF
IMCG
$4.12B
| $3.36M | 0.44% |
49,235
+11,134
| +29% | +$848K |
2024 Q4
1 quarter
|
|
55
Schwab US Dividend Equity ETF
SCHD
$111B
| $3.32M | 0.43% |
130,675
+6,963
| +6% | +$194K |
2024 Q4
1 quarter
|
|
56
iShares Gold Trust
IAU
$61.7B
| $3.27M | 0.42% |
52,155
+36,763
| +239% | +$1.99M |
2024 Q4
1 quarter
|
|
57
iShares Core MSCI Emerging Markets ETF
IEMG
$158B
| $3.26M | 0.42% |
62,742
+20,220
| +48% | +$1.09M |
2024 Q4
1 quarter
|
|
58
Avantis US Large Cap Value ETF
AVLV
$22B
| $3.2M | 0.42% |
52,913
+8,478
| +19% | +$575K |
2024 Q4
1 quarter
|
|
59
Fidelity Blue Chip Growth ETF
FBCG
$7.69B
| $3.17M | 0.41% |
84,867
+38,453
| +83% | +$1.74M |
2024 Q4
1 quarter
|
|
60
Vanguard Short-Term Bond ETF
BSV
$45.4B
| $3.16M | 0.41% |
40,381
+1,820
| +5% | +$141K |
2024 Q4
1 quarter
|
|
61
iShares 10-20 Year Treasury Bond ETF
TLH
$11.4B
| $3.14M | 0.41% |
31,173
+24,327
| +355% | +$2.47M |
2024 Q4
1 quarter
|
|
62
Sarepta Therapeutics
SRPT
$1.74B
| $3.09M | 0.4% |
57,509
+30,494
| +113% | +$3.21M |
2024 Q4
1 quarter
|
|
63
Capital Group Core Equity ETF
CGUS
$12.3B
| $3.09M | 0.4% |
98,398
+16,652
| +20% | +$585K |
2024 Q4
1 quarter
|
|
64
BlackRock Flexible Income ETF
BINC
$16.5B
| $3.06M | 0.4% |
59,076
+16,438
| +39% | +$861K |
2024 Q4
1 quarter
|
|
65
iShares S&P GSCI Commodity-Indexed Trust
GSG
$1.06B
| $3.04M | 0.4% |
140,987
-27
| -0% | -$607 |
2024 Q4
1 quarter
|
|
66
Alphabet (Google) Class C
GOOG
$4.27T
| $3M | 0.39% |
19,562
+2,018
| +12% | +$370K |
2024 Q4
1 quarter
|
|
67
iShares Russell Top 200 Growth ETF
IWY
$16.9B
| $2.93M | 0.38% |
14,671
-447
| -3% | -$103K |
2024 Q4
1 quarter
|
|
68
iShares 7-10 Year Treasury Bond ETF
IEF
$41.3B
| $2.93M | 0.38% |
30,945
+6,976
| +29% | +$653K |
2024 Q4
1 quarter
|
|
69
JPMorgan Equity Premium Income ETF
JEPI
$45.7B
| $2.88M | 0.37% |
53,651
-1,991
| -4% | -$116K |
2024 Q4
1 quarter
|
|
70
Franklin High Yield Corporate ETF
FLHY
$1.21B
| $2.85M | 0.37% |
121,951
+34,985
| +40% | +$840K |
2024 Q4
1 quarter
|
|
71
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
$3.06B
| $2.83M | 0.37% |
92,307
+79,335
| +612% | +$2.44M |
2024 Q4
1 quarter
|
|
72
iShares MSCI USA Momentum Factor ETF
MTUM
$19.8B
| $2.8M | 0.36% |
14,340
+5,192
| +57% | +$1.11M |
2024 Q4
1 quarter
|
|
73
Strategy Inc
MSTR
$60.7B
| $2.76M | 0.36% |
8,687
+3,919
| +82% | +$1.24M |
2024 Q4
1 quarter
|
|
74
Arista Networks
ANET
$258B
| $2.74M | 0.36% |
38,443
+4,604
| +14% | +$467K |
2024 Q4
1 quarter
|
|
75
SPDR Gold MiniShares Trust
GLDM
$30.9B
| $2.72M | 0.35% |
41,336
+7,114
| +21% | +$404K |
2024 Q4
1 quarter
|
|
Similar funds
TIM
AFCM
ACM
DIP
CS
B
LIA
WTA
Sovran Advisors's Q1 2025 Portfolio in Review
As of Q1 2025, Sovran Advisors held 481 positions worth $770M, up 9.8% from $702M the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Sovran Advisors deployed $130M of net new capital in Q1 2025, opening 73 new positions and adding to 256 existing holdings. Its largest new stake was Novo Nordisk: 36,559 shares worth $2.12M.
By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 75% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was PIMCO Dynamic Income Fund, an estimated $2.67M trimmed.
- Sovran Advisors's largest Q1 2025 buy was Novo Nordisk: 36,559 shares worth $2.12M.
- Sovran Advisors added most to Qualcomm in Q1 2025, an estimated $7.21M increase.
- Sovran Advisors's biggest Q1 2025 reduction was PIMCO Dynamic Income Fund, cutting an estimated $2.67M.
- Sovran Advisors fully exited Celldex Therapeutics in Q1 2025, selling an estimated $2.6M.
- Sovran Advisors's ten largest holdings make up 20% of its $770M portfolio in Q1 2025.
- Sovran Advisors opened 73 new positions and closed 26 in Q1 2025.
- Sovran Advisors's portfolio value rose 9.8% quarter-over-quarter to $770M.
Based on Sovran Advisors's 13F filing for Q1 2025, filed 25 Apr 2025.